`LINGUAL
`
`CROSSLINGUAL, LLC
`3736 Fallon Road, Suite 226
`Dublin, CA 94568
`Tel: 206-851-7932
`
`hr@clingua|.com
`
`AFFIDAVIT OF TRANSLATION
`
`I, Alan F. Siegrist, of CROSSLINGUAL, LLC, hereby declare that:
`1.
`I am fluent in Japanese and English.
`2.
`I am an active member of the American Translators Association and a Certified
`
`Translator of Japanese to English.
`3. The English translation attached to this declaration is an accurate and correct
`translation of the following document, attached hereto:
`2002.6 - 2nd Edition [Bronuck Package Insert]
`I declare that the foregoing is true and correct to the best of my knowledge.
`
`Executed on October 29, 2015
`
`Certification #63788
`
`Alan F. Siegrist, CT
`CROSSLINGUAL, LLC
`ATA Member No. 31889
`
`A notary public or other officer completing this certificate verifies only the identity of the individual who signed the
`
`documents to which this certificate are attached, and not the truthfulness, accuracy, or validity of that document.
`
`State of California, County of
`On Oolvlw 2°: aoxs
`personally appeared
`‘F,
`91‘; S J
`who proved to me on the basis of satisfactory
`
`evidence to be the person whose name is subscribed to the within instrument and acknowledged to me
`that he executed the same in his authorized capacity, and that by his signature on the instrument the
`person, or the entity upon behalf of which the person acted, executed the Instrument.
`
`I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing
`paragraph is true and correct.
`
`Witness my hand and fficial seal.
`
` MCQIIELIIIE rum soucutl
`:
`coma. _a2105829
`NolaryPiolic-Cailoinia
`.5£Ii9
`
`
`
`
`IOUN
`
`PAGE 1 OF 5
`
`SENJU EXHIBIT 2112
`
`LUPIN v SENJU
`
`IPR2015—0l105
`
`
`
`‘June 2002 — Revised (Second Edition)
`May 2000 — Created
`Storage Method: Room temperature storage
`lkpiration:
`Tobeusedbytheerqlvirationdatedisplayedontheexteriorpadrage
`(evenbelixeexpiratiorgtobeusedpromptlyafieropening).
`
`Japan Standard Commodity Classification No. 871319
`21200AMZ00168
`
`1997
`
`2000
`
`J
`I
`
`Non-steroidal anti-inflammatory ophthalmic agent
`
`Designated Prescription Drug BRONUCKO OPHTHALMIC SOLUTION
`Bromfenac sodium hydrate ophthalmic solution
`
`
`.2B
`
`
`The following adverse efl'ects were observed in the foregoing
`o
`
`s
`
`lepharitis, conjlmctival hyperemia, stinging, ocular pain
`(temporary), corneal inflammation, corneal epithelial abrasion
`superficial punctate keratitis, follicular conjunctivitis, pruritus,
`and bnrnin sensation
`'ds
`
`When manifested. administration is suspended.
`3. Administration to Pregnant, Parturient, and Nursing
`Women
`
`Administration is to be conducted to pregnant woman or
`women who may have conceived and to women who are
`nursing only when it is judged that the benefits of treatment
`outweigh the risks.
`(The safety of administration during pregnancy and lactation
`has not been established.)
`4. Administration to Children
`
`Safety relative to children has not been established (there is
`little experience with use).
`5. Cautions for Use
`
`(1) Administration route: only to be used for ocular instillation
`(2) At time of administration: during ocular instillation. take
`care so that the lip of the container does not directly contact
`the eye.
`[Pharmaeokineties]
`(Reference)
`Intraocular Migration <rabbits>l)
`In testing wherein ocular instillation of 0.05 mL of 0. 1% “C-
`bromfenac sodium hydrate ophthalmic solution was conducted
`once a day is both eyes of rabbits. and radioactivity was
`measured after 15 minutes. 30 minutes. and 1. 2. 4. 8. 32. 24.
`48. and 72 hours. elevated values were observed in the cornea.
`conjunctiva. and anterior sclera.
`At 72 hours after ocular instillation. all ocular tissue except
`for the lens was below the detection limit (0.1 ng eq./g or
`mg 5: rgr'mt',
`I0‘
`0--‘Corina
`tj.. . .3
`'Conjum:tiva
`‘Anteriorsclera
`'AntuIorvltreouslnnmr
`.Blood
`
`
`
`
`
`
`
`Bromfenacsodiumhydrateconcentration
`
`[Contraindications (do not administer to the following
`patients)]
`Patients with a previous history ofhypersensitivity to the
`in clients ofthis dru
`
`Co osition/Pro‘
`'
`
`Ingedients / content
`_
`Brornfenac sodiumhydrate 1 mg
`Boric acid, borax, dry sodium sulfite, sodium
`edetate, povidone, polysorbate 80,
`sodium:
`
`'Addifiws
`
`V-~ xide
`
`‘E:
`11!;
`[Effieaey / Effects]
`Symptomatic treatment of inflammatory ailments of the
`external eye and anterior eye (blepharitis. conjunctivitis.
`episcleritis).
`postoperative
`scleritis
`(including
`and
`inflammation)
`[Usage I Dosage]
`Ordinarily. 1-2 drops per administration. and 2 ocular
`instillations per day.
`[Cautions for Use]
`1. Important Basie Cautions
`(1) Keeping in mind that treatment by this drug is symptomatic
`treatment rather than causal
`treatment. and that
`it
`is
`reported that serious liver damage (including death) has
`been
`observed
`in patients
`subjected
`to
`long-term
`ad.ministration of 1 month or more with the oral agent of
`bromfenac sodium. continuous administration for 4 weeks
`
`or more is not conducted in principle. Although the
`aforementioned adverse eflects observed with the foreign
`oral agent were due to long-term administration exceeding
`the approved usage and dosage. sales have been voluntarily
`suspended.
`(2) As there is risk that eye infection may become subclinical.
`in case of use on inflammation resulting from infection.
`administration is to be conducted carefully with adequate
`observation.
`2. Adverse Effects
`
`At the time of approval. adverse eflects had been observed in
`16 out of a total of 423 cases (3.78%).
`With respect to the content of adverse effects. there were
`3 cases of blepharitis
`(0.71%).
`3
`cases of conjunctival
`hyperemia (0.71%). 3 cases of stinging (0.71%). 3 cases of
`'
`(temporary)
`(0.71%).
`2 cases of
`corneal
`inflammation (0.47%).
`1 case of conical epithelial abrasion
`(0.24%). 1 case of superficial plmctate keratitis (0.24%). 1 case
`of follicular conjunctivitis (0.24%). 1 case of pruritus (0.24%).
`and 1 case of burning sensation (eyelids) (0.24%) (at the time of
`approval).
`
`PAGE 2 OF 5
`
`
`
`[Principal Literature]
`1) Mitsuyoshi Isaka et al.: Pharmacokinetics, 14 (1) 32, 1999
`2) Takahiro Ogawa et al.: Journal of Japan Ophthalmology Society, 99, 406, 1995
`[Contact for Requesting Literature]
`Scientific Information Department
`Senju Pharmaceutical Co., Ltd.
`5-8, Hirano-machi 2-chome, Chuo-ku, Osaka-shi, Osaka
`
`Marketed by: Takeda Pharmaceutical Co., Ltd.
`
`1-1, Dosho-machi 4-chome,
`
`Chuo-ku, Osaka
`
`Package 02-075
`
`
`
`
`
`
`
`
`
`Efficacy rate (%) and
`effectiveness
`66.7 (6/9)
`63.2 (60/95)
`63.6 (7/11)
`86.4 (152/176)
`77.3 (225/291)
`
`relative
`
`to
`
`experimental
`
`[Clinical Results]
`A summary of results with respect to 291 cases including
`double-blind comparative testing are shown in the table.
`For the most part, daily dosage and administration period
`were 1 drop per administration and 2 administrations per day
`over a 2-week period.
`Table. Clinical Effects by Ailment
`Name of ailment
`Blepharitis
`Conjunctivitis
`Scleritis (including episcleritis)
`Postoperative inflammation
`Total
`[Pharmacoefficacy and Pharmacology]
`1. Pharmacological Action
`(1) Anti-inflammatory
`action
`conjunctival chemosis in rats2)
`It was observed that Bronuck ophthalmic solution exhibited
`anti-inflammatory action relative to experimental acute
`conjunctival chemosis in rats induced by arachidonic acid
`and carageenin.
`(2) Inhibitory effects relative to increases in aqueous humor
`protein concentration in rabbits after anterior chamber
`paracentesis or after laser irradiation2)
`It was observed that Bronuck ophthalmic solution almost
`completely inhibited increases in aqueous humor protein
`concentration in rabbits after anterior chamber paracentesis
`or after laser irradiation.
`2. Mechanism of Action
`In tests using rabbit iris-ciliary bodies2) and bovine seminal
`vesicles, it was confirmed that inhibitory action was exhibited
`against production of prostaglandin inflammatory mediators via
`cyclooxygenase (in vitro).
`[Physicochemical Findings Relative to Active Ingredients]
`Generic name:
`Bromfenac Sodium Hydrate (JAN)
`Chemical name:
`sodium 2-amino-3-(4-bromobenzoyl)
`phenylacetate sesquihydrate
`Molecular formula: C15H11BrNNaO3 · 1½ H2O
`Molecular weight: 383.17
`Structural formula:
`
`
`Properties:
`
`
`
`
`Bromfenac Sodium Hydrate is an odorless
`crystalline powder of yellow-orange color.
`It is freely soluble in water, soluble in
`methanol, slightly soluble in ethanol
`anhydride, and practically insoluble in
`acetonitrile or ether.
`
`[Packaging]
`5 mL × 10, 5 mL × 50
`
`
`
` Manufactured by: Senju Pharmaceutical Co., Ltd.
`
`
`5-8, Hirano-machi 2-chome,
`
`
`Chuo-ku, Osaka
`
`PAGE 3 OF 5
`
`
`
`*2oo2$6HF&3I(§$2Ifi)
`20()05¥55Hf’I3fiE
`
`33 I éfiflfi
`1!?
`f£IFJ19lF.fi35'I~fi€ZiEfJW)1!!¥i39illiV~Jl1fiFfl1‘Z> J: t (MFBMHEINT
`591$. l#i逑If£Iifi’§°7)\l:1¢lfiH‘Za:. t).
`
`H$fii!!mfi‘:5}fi§%
`
`#=m%
`minim
`WWW
`Maw:
`
`3517‘-I214 Ffifififinfilflfil
`
`W“ 7'DT'997."—§flEii§
`
`BROPUCCOPHTHALMIC SOLUTION
`7ElA7I7'77' l~'J'Db. 7J<$fl% Ififiifi
`
`(§.§(7fi0)§§l:lat!'Q5'.+b7;L\a.':é:)l
`
`#m®mfitflL£&fim%flE0&b$%
`
`H552 - 1£*.=lfil*
`
`“Em?
`
`*ifiIJll%
`
`:1:-7m d:-71?}. 9211::-¢ita+wr>A, .1-.—7'
`}~&')'|~‘) -‘IA. a‘!l:'l~‘I/\ =‘K')‘))I/«\'—-l~80\
`mm«>v»::oA\*mm++uvA
`
`E
`
`pH
`
`Acrmuurax
`fififfiflfl
`
`&o~&e
`
`Mm
`
`L1TVJEJ1’F}fi l1L3EV>fl§'C‘§26b 5 H7: *5 0)'C‘fi26o
`
`name. ififiiillll. Ifillfifi. flEfi[*$'E£]\
`fiflfifl. fllRI.EZ§UK\ fiflfifififi
`52. smma. =!fi1¥!%\ §!‘.H%[BE|&]
`
`iii)‘-§é31 L7‘:i%€N:li.
`
`-f5?3§é'FPJl:'3"r.'.> C. to
`
`a&fi.§fi\Hflfi%«®fl5
`&fiXu&fiLtw6W%&o&5fiA&U&%¢w
`
`fikuumfitwfifififlflafiéxflatflfiéh
`5%%u®&&5#5:&o
`
`EfifiwkvfifimmflficwfafififiumfiLrw
`awd
`
`¢¢fi%«®&5
`
`$%$uNT6££fiu%fiLrwcwwflmfififlw
`awn
`
`(ME - QR)
`
`afifliwfit
`
`9l~flEflJ5i?J‘i1‘ifflEt.‘B€)%2a&Et‘Ea§é.§.o)ira‘J:i§9fii5EEflfivfik gm
`52.
`-3‘alfi52(,l:fiIE5é’5:‘é.‘U)\ fiffééfléfil
`
`IKE‘ fill
`
`fil#\1E]1"'2ifi\ 1H
`
`lfimxmzfil
`1.i:>;-zzcaasm
`
`(1)21=?fIH: ; Z»iéiJfilifiii<l#EEii*ET*l;t72:<>?9‘11'F‘.fil‘2E“(‘§;z>
`:tKfifiL.it.flEK£wf.7nA7;+
`
`1: FlL1_[:ElUH":‘z‘-5 Lf:.§.
`7 *9‘ F ‘J '7 A0)¥§CI7FJ’&l
`‘Z‘&:ifl72fl¥fi§(?Et>E‘.%.‘ir)7)‘?é!.8f>Bflfctwfl
`
`lfifillt L1 4:Ell51L1J;0)flEfi&%‘«z;t
`€_‘H)"§)60)'C'.
`fi=b7.‘a:w:2:o 73:15. 5'1-I§]0)flaElfiJ6:?£af)I‘oz‘L7‘:_h
`
`3Ema1Jf’£fiH&1fii:;%20)}¥Ji£-mfiirfliifcfiwlfifi-i:
`J; 6 %>0)'c*&;z:7)*.
`I§l3:B9c:IE'ai‘:’5:rIJ1|;LTu»7.>o
`
`(2)flflr7>!wM;‘1§£—3f<E14a4I:'§‘i£»srsi-n>b<35230)'G. ZERE
`
`t;6&finfiLfmwb%fiuufl$&+fiufi
`tn. 1££fit:§2‘é'r7.»: an
`
`2.3mm
`
`23:i£B'€r'c*a>§:#i‘-;{9I423f9IJ rmefil (3.78%) c:mf’rsFfl7:*‘r.=;2ai;
`Bhfco
`
`fillffiiflwfili. uam234¢<o.719e).
`
`ie*.'lEifiJm3f‘H0.71
`
`96). iimuasitr-(0.71%)\ amt ~i&1&]3{4=(o.71%). its
`
`E§iH21¢(0.47%). fflfilfliiidllill’-F(0.24%)~
`
`Eflafifié 1 {4“~(024%)\ swans 1 {4F(024%). ififi‘-$1
`14 (024%)‘
`.1.&$[EEw] 1{4=(024%) The is (z}‘<%Zfl#)o
`
`PAGE 4 OF 5
`
`m&s&g:fiwmuoawm¢a:a°
`
`Hm5fi:mw0&3\§%®%##fifiHKmh
`&w;5KEfiT5:a°
`
`Ifiimlbflfil
`(G %)
`llflfifi ("Hi-=1-')"
`'1 '7L Jkfllw fimifi
`'7'‘i'-'¥¢)W§RL'.0.1%'‘C-7UA‘7:.‘i'7'}‘ }‘
`0.05mL’5: l [til]:-KWL. 15‘ 305% 1‘ 2. 4. 8. 12. 24. 48. 7235‘
`l|lifiE£:E5£!h‘i?i"I£E>EillJ£Lf:3t&‘C*£:t. fih. Sfifllilflflifififimz
`iFHii’E>‘I'<L7‘:a
`fimfinfimvu‘x&#%k<t&rwmm&?mwm%
`(0.lng eq./g or mL).L1 F’C‘§:o 71¢
`
`-01! I
`one :3 [
`-—- Ilflfififlfl
`o--a :mJm<
`A—-A :[m Sfi
`\\\\\\\\\: tiflilflfl-1:1?
`n=3
`
`
`
`H333}I-‘QC'7"+\‘I"|'H\JI>D\|.
`
`
`
`-
`—
`jEwfiwE}“‘
`:m§&w&%mam&€bmnwtomrwmafiauiwe
`fi0T&5.'
`~;’
`5
`&£\IB&%fi.&5Mmufi%fi#1@1fi.1B2@.2£
`m?t5o
`~
`‘
`
`i. fififlllflfifiiilflé
`
`-
`
`m$<%>WM A
`
`%
`
`%
`
`I
`
`IEEIEI
`1) #=‘fi5’:'3B.c!I I fifififliafi. 14(1). 32. 1999.
`2) Ibifilfiifiuz 2 El 2liE$I*¥%#i-*3. 99. 406. 1995.
`«.1.
`
`'lxzwx.:i:1z9’a1
`‘I’-#%!¥49fi3a."<£z%t
`
`‘
`‘—‘¥=ifi‘l‘%¥lh“:‘i5
`
`.
`
`$541-0Q46,.2t_fiifit1=9&IX$EfNI:TB 5&8?
`
`'
`
`I¥wE§§l"
`-
`Lx2¢m,,=n ‘
`*
`Kflfivbififlfiflflflufififififififi”
`7U#v?fimfifi59FE£U5?fi#FV&yfi5V;
`ya;a%mws&fiH#mc#Lfi&fi#me$?:t#
`
`»
`
`‘-,§§Jb1’o#‘L"C|/\Z>o
`
`"
`
`:
`
`A
`
`A
`
`m¢fi¥m§$m§1uu—fi—fi$§wM#EEflEflmu
`wvawmmx”
`_
`--
`.
`.
`.7W%v?fiEfiu7#¥K£W6fi§%W&XuVe¥—
`fifl&@E#§Efi&mm&uH%£uMfi¢5:2%?»
`snrnxaa
`
`V;
`zfiE§H_
`‘é#¥u%%mfifi&wvvm§&mmnaauswr\va
`ut$9V+—fi&fiT67uxy757VV%®&fix?4
`:—y—mmmmwme$¢:ammasnrwamnmw;
`
`lfii?flfi!t'.53'lCf$§,'§'53!‘flS$3|':“JHlfi.] -
`—'flQ£ I ‘7U.£\7::_‘7‘7‘T I" ‘_J VJ-x Jkfllw‘
`_
`(Bromfenac Sodium Hydrate) UAN]
`'f|.’.§P% 3 sodium 2-amino-3~(4-bromobenzoyl)phenylacetate
`scsquihydrate
`
`5}-Ht 2 Cx.sHuBrNNa0: - 1é—Hzo
`534% 1383.17
`"
`T
`fifiil
`
`,
`
`Br’
`
`.
`
`.
`
`0
`II
`C '
`
`4
`
`~
`
`H,N
`
`cH,Co,Na v 11/21-1,0
`
`:7uA7;+a+buwA#m&u.fie~m@o§&
`i$a)w5R‘t-.
`l::sw;t7&wo
`-
`
`- 7fcb:i§lj'R='§'<. X5?/—Jvl:~?=<’i$U'*t-"§‘<. mm;
`5')-.-Jw:fiafi:< <, 7-I2 ]~.: }~ I) wXh‘.:'.—-7-M:
`lit/uaiatiffivwo
`
`FE “$3
`5mLx1o.5mLg5o
`
`PAGESOFS
`
`mfifimfifllfififififi
`i:Efi?I#=§elZ:‘§3§IfIIJET a1$1% :
`
`-
`
`.
`
`-
`
`'